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Abstract
BACKGROUND: Diabetic retinopathy is an emerging microvascular complication of diabetes mellitus and a causes 
of blindness in individuals between ages 30 and 70 years, which is characterized by increased proliferation of 
blood vessels, vascular occlusion, angiogenesis, loss of pericytes from retinal capillaries, microaneurysms, retinal 
bleeding, increased retinal capillary permeability, thickening of capillary basal membranes, and infarcts that affect the 
retina, induced to permanent blindness.
AIM: This study aimed to find the role of receptor advanced glycation end products (RAGE) inhibition in lowering the 
vascularization process which causes a decrease in retinal function on diabetic retinopathy.
MATERIALS AND METHODS: This research was an in vivo experimental study. A total of 30 male Wistar rats 
(200 ± 20 g) were obtained from Eureka Research Laboratory (Palembang, Indonesia). Experimental animals 
were placed in cages under controlled conditions (12 h of light/dark cycles with temperatures of 22 ± 1°C and 
humidity of 40–60%), fed and drank ad libitum. White rats were induced by diabetes mellitus using alloxan at a 
dose of 120 mg/kgBW, intraperitoneally, accompanied by drinking 10% glucose solution for 140 days. Furthermore, 
experimental animals were grouped into five groups (at eight animals per group), Group 1: Normal control, Group 
2: Negative control (induced diabetics retinopathy and given intravenous aquadest), Group 3: Given anti-RAGE 1 
ng/mL, Group 4: Given anti-RAGE 10 ng/mL, and Group 5: Given anti-RAGE 100 ng/mL. Giving anti-RAGE was 
done in a single dosage and intravitreal. After the rats were sacrificed by intraperitoneal injection of 10% chloral 
hydrate, the evacuation of the eye’s retinal tissue was then carried out, fixed in a 4% paraformaldehyde buffer for 
immunohistochemistry examination of the eye’s retinal tissue. Evaluation of the expression of nuclear factor-κβ (NF-
kB) and intercellular adhesion molecule-1 (ICAM-1) used Image J Software so that the percentage of NF-kB and 
ICAM-1 expression would be obtained.
RESULTS: Negative control group showed an increase in NF-kB expression in the retinal tissue of diabetic 
retinopathy rats. Administration of anti-RAGE showed its potential to suppress NF-kB expression in retinal tissue of 
diabetic retinopathy white rats as well with an increase of anti-RAGE dose from 1 ng/mL to 100 ng/mL. Activation of 
NF-kB causes activation of the inflammatory cascade, which is characterized by the production of pro-inflammatory 
cytokines, one of which is ICAM-1. Giving anti-RAGE could suppress the expression of ICAM-1 along with an 
increase in anti-RAGE dose.
CONCLUSION: Anti-RAGE is able to block the inflammatory process, by inhibiting the expression of NF-kB and 
ICAM-1 in the retinal tissue of diabetics retinopathy in white rats.
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Introduction
Diabetes mellitus has been being an emerging 
health problem since the past two decades. The 
International Diabetes Foundation in 2014 estimated 
the number of people with type 2 diabetes mellitus 
worldwide at 387 million, and this number is expected 
to increase to 552 million by 2030. Diabetic retinopathy 
is a serious microvascular complication of diabetes and 
a major cause of blindness in individuals between ages 
30 and 70 years, which is characterized by increased 
proliferation of blood vessels, vascular occlusion, 
angiogenesis, loss of pericytes from retinal capillaries, 
microaneurysms, bleeding, increased retinal capillary 
permeability, thickening of capillary basal membranes 
and infarcts that affect the retina of the eye, leading to 
blindness [1], [2], [3]
Most of all diabetes mellitus patient either type 
1 or type 2 show lesions on the retina after 20 years 
of hyperglycemia. The upcoming lesion is a result of 
the hyperglycemia condition through the biochemical 
mechanism of the polyol pathway, the formation of 
advanced glycation end products (AGE), activation 
of protein kinase C, oxidative stress or the formation 
of reactive oxygen species (ROS), and hexosamine 
pathway. From these various pathways, the formation 
of AGE products becomes the mechanism that plays 
a significant role in initiating the incidence of diabetic 
retinopathy [4], [5].
The interaction between AGE and its 
receptor, receptor AGE products (RAGE), increases 
the production of intracellular ROS and upregulation 
of nuclear factor-κβ (NF-κβ) transcription factors and 
their products, endothelin-1, vascular cell adhesion 
molecule-1, intercellular adhesion molecule-1 (ICAM-1), 
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vascular endothelial growth factor, pro-inflammatory 
cytokines interleukin-1α (IL-1α), IL-6, and tumor 
necrosis factor α. This will cause the activation of the 
inflammatory process which will cause tissue damage 
accompanied by a wound healing process, in the form 
of a collagenization and fibrosis process, which in turn, 
will end in damage to the function of the tissue, in this 
case retinal tissue [6], [7], [8].
AGE inhibition through RAGE receptor 
inhibition is a therapeutic promising to inhibit the 
inflammatory cascade, which forms the basis of the 
pathophysiology of diabetic retinopathy. This study is 
a continuation of the previous research, which seeks 
to see the role of RAGE inhibition in decreasing the 
vascularization process which causes a decrease 
in retinal function in the case of diabetic retinopathy. 
Efforts to explore the mechanism of action pathway 
continue in this study, where the inflammatory pathway 
is the target of further exploration [8].
Materials and Methods
This research is an in vivo experimental study. 
A total of 30 male Wistar rats (200 ± 20 g) were obtained 
from Eureka Research Laboratory (Palembang, 
Indonesia). Experimental animals were placed in cages 
under controlled conditions (12 h of light/dark cycles 
with temperatures of 22 ± 1°C and humidity of 40–60%), 
fed, and drank ad libitum. All animal treatments and 
experimental procedures were approved by the Ethics 
and Humanities Commission of the Faculty of Medicine, 
Universitas Sriwijaya (No.243/kptfkunsri-rsmh/2019).
White rats were induced to be diabetes mellitus 
using alloxan at a dose of 120 mg/kgBW, intraperitoneally, 
accompanied by drinking 10% glucose solution for 140 
days. Furthermore, experimental animals were grouped 
into five groups (at eight animals per group), Group 1: 
Normal control, Group 2: Negative control (induced 
diabetics retinopathy and given intravenous aquadest), 
Group 3: Given anti-RAGE 1 ng/mL, Group 4: Given 
anti-RAGE 10 ng/mL, and Group 5: Given anti-RAGE 
100 ng/mL. Giving anti-RAGE was done in a single 
dosage and intravitreal.
After the rats were sacrificed by intraperitoneal 
injection of 10% chloral hydrate, the evacuation of the 
eye’s retinal tissue was then carried out, fixed in a 4% 
paraformaldehyde buffer for immunohistochemistry 
examination of the eye’s retinal tissue. After the 
tissue that had been put into the fixation fluid, the 
next process was dehydrated using alcohol and 
xylene, then paraffinized and then cut as thick as 
5 um using a rotary microtome (Leica). Next, it was 
placed on coated-object glass. Then, rehydration is 
carried out on the tissue using xylene and alcohol 
with a concentration of 96%, 90%, 80%, and 70% and 
rinsed with tap water. The next stage, retrieval antigen 
was carried out with the HIER (Heat Induced Epitop 
Retrieval) method, where the slides were put into a 
citrate buffer solution, then heated at a temperature 
of 95oC for 60 min. Then, NF-kB 1: 700 (Cloud Clone) 
antibody was painted; ICAM-1 antibody 1: 700 (Cloud 
Clone), followed by overnight incubation at 4°C. The 
next stage was to paint with a secondary antibody, 
Biotinylated-Horseradish Peroxidase, incubated for 
1 h, at room temperature. Next, chromogen was given 
to the tissue. Furthermore, the dehydration process 
was again carried out using concentrated alcohol and 
xylene. The next step was mounting and evaluating 
the expression of NF-kB and ICAM-1 using Image J 
Software so that the percentage of NF-kB and ICAM-1 
expression would be obtained.
All data were presented as mean ± standard 
deviation and all statistical analyzes were performed 
with the SPSS 25 (IBM) program. One-way ANOVA 
followed by post hoc analysis was carried out to assess 
differences in the mean expression levels of each 
protein. p < 0.05 was determined as an indication that 
there were significant differences in the mean levels.
Results
It is believed that NF-κB is the main regulator 
in the activation of pro-inflammatory cytokines. From 
Table 1, it was clearly stated that negative control group 
has an increase in NF-kB expression in the retinal 
tissue of diabetic retinopathy rats. Furthermore, there 
was higher expression of NF-ΚB in negative control 
group which was shown by brownish image in Figure 1. 
The administration of anti-RAGE showed its potential to 
suppress NF-kB expression in retinal tissue of diabetic 
retinopathy white rats as well with an increase of anti-
RAGE dose from 1 ng/mL to 100 ng/mL.
Activation of NF-kB causes activation of the 
inflammatory cascade, which is characterized by 
the production of pro-inflammatory cytokines, one of 
which is ICAM-1. Figures 2 and 3 show that in diabetic 
retinopathy was an increase in the expression of 
ICAM-1 in the retinal tissue of white rats. Giving anti-
RAGE can suppress the expression of ICAM-1 along 
with an increase in anti-RAGE dose.
Table 1: Level of NF-kB expression in retinal tissue retinopathy 
diabetics
S. No. Group NF-kB (%) ± SD p value*
1. Negative control 70.62 ± 2.95 0.00
2. RAGE 1 ng/mL 66.98 ± 5.08 0.00
3. RAGE 10 ng/mL 48.22 ± 4.27 0.00
4. RAGE 100 ng/mL 26.66 ± 3.28 0.00
5. Normal 5.45 ± 1.31 -
*VS normal; ANOVA, post hoc Bonferroni; p < 0.05. RAGE: Receptor advanced glycation end products, 
NF-κβ: Nuclear factor-κβ.
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Discussion
This study found a significant difference 
between the treatment groups in diabetic retinopathy 
white rats that had been given anti-RAGE antibodies 
against NF-κβ expression where in higher dose of 
Figure  1:  Effect  of  anti-receptor  advanced  glycation  end  products 
(RAGE) on nuclear factor-κβ expression in retinal tissue retinopathy 
diabetics rats. Immunohistochemistry assessment. Normal: Normal 
group, Negative control: Retinopathy diabetics rats, RAGE 1 ng/mL: 
RAGE 1, 10, and 100 ng/mL: Anti-RAGE doses 1, 10, and 100 ng/mL 
+ Retinopathy diabetics. Magnification ×400
anti-RAGE antibody (100 ng/mL) was more effective 
than the administration of a dose of 10 ng/mL because 
higher dose obtained percentage of NF-κβ expression 
of 26.66% ± 3.28 while giving 10 ng/mL of 48.22% ± 
4.27. AGE-RAGE bonds were able to induce endothelial 
dysfunction and cause hyperpermeability.
Figure  2: Effect  of  anti-  receptor  advanced glycation  end products 
(RAGE) on intercellular adhesion molecule-1 (ICAM-1) expression 
in retinal tissue retinopathy diabetics rats. Immunohistochemistry 
assessment. Normal: Normal group, Negative control: Retinopathy 
diabetics rats, RAGE 1 ng/mL: RAGE 1, 10, and 100 ng/mL: 
Anti-RAGE doses 1, 10, and 100 ng/mL + retinopathy diabetics. 
Magnification ×400
At the cellular level, the AGE-RAGE bond 
could induce nuclear activation and translocation of 
NF-κβ (a transcription factor capable of responding 
to adhesion molecules in endothelial or leukocytes) 
which would initiate vascular disorders. Activation of 
NF-κβ would also induce activation of pro-inflammatory 
cytokines. Activation of NF-κβ also played a role in the 
occurrence of apoptosis, because it made an increase 
in the factor of proapoptosis bax (bax-caspase 
protease pathway). RAGE expression depends on 
the amount of NF-κβ, which was a positive feedback 
response to increased RAGE expression through 
AGE-RAGE interactions. Others study concluded 
that anti-RAGE treatment in diabetic retinopathy mice 
could lower pro-inflammatory cytokines such as NF-kβ 
and IL1β [3], [9], [10], [11], [12], [13].
Figure  3:  Effect  of  anti-receptor  advanced  glycation  end  products 
on intercellular adhesion molecule-1 expression in retinal tissue 
retinopathy diabetics rats. * p < 0.05 versus normal; ANOVA, post 
hoc Bonferroni
This research also found a notable difference 
between the treatment groups in white rats with diabetic 
retinopathy models who had been given anti-RAGE 
antibodies to ICAM-1 expression where the dose 
of anti-RAGE antibody at a dose of 100 ng/mL was 
more effective than lower dose (10 ng/mL) because 
administration of 100 ng/mL obtained percentage of 
ICAM-1 expression of 16.71 + 3.10 while administering 
10 ng/mL of 33.38 + 5.09. Giving anti-RAGE 
100 ng/mL is considered more effective in reducing 
ICAM-1 expression.
NF-kB has correlation and relationship 
with ICAM-1 expression. NF-kB activation activates 
the inflammatory cascade, which is characterized 
by secretion of pro-inflammatory cytokines and 
mobilization of neutrophils at the inflammatory site. 
The mobilization of neutrophils will cause activation of 
ICAM-1, which is an adhesion molecule of neutrophils, 
so as to facilitate the movement and mobilization of 
neutrophils. The results of this study indicate that an 
increase in NF-κB is followed by an increase in ICAM-1 
in diabetic retinopathy. Anti-RAGE is able to break the 
cascade of NF-kB activation through the activation of 
AGE receptors (RAGE) [14], [15], [16], [17] This study 
reinforces previous studies also showing the potential 
of anti-RAGE in preventing angiogenesis activation in 
diabetics retinopathy. The ability to inhibit angiogenesis 
in anti-RAGE administration through inhibition of the 
inflammatory pathway through inhibition of NF-kB and 
ICAM-1 [8].
Conclusion
Anti-RAGE is able to block the inflammatory 
process, by inhibiting the expression of NF-kB and 
ICAM-1 in the retinal tissue of diabetics retinopathy in 
white rats.
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